NewcelX Ltd. (NCEL NASDAQ) stock market data APIs
$3.3002
-0.02(-0.6%)
as of September 11, 2026
Try our APIs with
free plan!
NewcelX Ltd. Financial Data Overview
Price chart is built with
Anychart
NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders. It also develops iTOL-102, NCEL-201, NCEL-301, and NCEL-007. NewcelX Ltd. was founded in 2008 and is headquartered in Kloten, Switzerland.
Prev. Close
3.3002
Open
3.2798
High
3.3122
Low
3.2327
52 wk Range
1.83-24.6
Market Cap
19 087 K
Shares Outstanding
5 776 K
EPS
-1.05
Beta
0.574
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get NewcelX Ltd. data using free add-ons & libraries
Get NewcelX Ltd. Fundamental Data
NewcelX Ltd. Fundamental data includes:
- Net Revenue:
- EBITDA: -2 507 000
- Earnings Per Share: -2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-06
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
NewcelX Ltd. News
New
NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform
Study published in Stem Cell Reportsdemonstrates that AstroRx® - a therapy derived from NewcelX’s platform -addresses key barriers toremyelination with potential to treat chronic demyelinating dise...
Top Biotech Gainers: TNGX Hits New High, ALVO Moves Closer To FDA Approval, ZVRA, IDYA Turn Heads
(RTTNews) - Today's top gainers include Tango Therapeutics, following encouraging pancreatic cancer trial data; Aspire Biopharma, ahead of upcoming milestones; Alvotech, after FDA acceptance of its in...
NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference
ZURICH, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL),– NewcelX Ltd. (Nasdaq: NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived thera...
Narcolepsy Market is Projected to Grow at a CAGR of 5.6% During the Forecast Period (2025-2034) Due to Increasing Disease Awareness, Improved Diagnosis, and Expanding Therapeutic Options | DelveInsight
The narcolepsy market landscape is evolving from symptomatic management toward targeted, mechanism-based approaches that address the underlying neurochemical dysregulation of the orexin system. New dr...
Get NewcelX Ltd. fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
